NVAX - Novavax Inc logo

Novavax Inc

NVAX

Novavax, Inc. is a biotechnology company focused on discovering, developing, and commercializing vaccines for infectious diseases. Its key products include Nuvaxovid, a COVID-19 vaccine, and a malaria vaccine utilizing R21 Matrix-M adjuvant.

โš•๏ธ Healthcare NASDAQ Listed 1995 $ USD
$1,000 invested 30 years ago โ†’$120today

Score Overview

1 Year
Score
Net Growth-156.26%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-63.17%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score6.0
Net Growth85.79%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth-63.90%
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth11.51%
Net Trend60%
Net Income Consistency
Rev Growth26x
Rev Trend70%
Revenue Consistency
20 Years
Score3.3
Net Growth-8x
Net Trend40%
Net Income Consistency
Rev Growth88x
Rev Trend60%
Revenue Consistency
30 Years
Score
Net Growth-43x
Net Trend43%
Net Income Consistency
Rev Growth4137x
Rev Trend57%
Revenue Consistency
All Time
Score
Net Growth-43x
Net Trend43%
Net Income Consistency
Rev Growth4137x
Rev Trend57%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Novavax Inc has ranked, year by year

Measure
Fundamentals Window

Showing 1 year ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • NVAX

2001: 82.2% ยท 2021: 57.0% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 10.80โ€”
1 Year2025-09-26
$ 8.5526.32%
5 Years2021-09-28
$ 204.83-94.73%
10 Years2016-09-28
$ 44.00-75.45%
20 Years2006-09-28
$ 80.80-86.63%
30 Years1996-09-27
$ 90.00-88.00%
All Time1995-12-05
$ 80.00-86.50%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 413M-$ 247M$ 719M
2025$ 1.12B$ 440M$ 735M
2024$ 682M-$ 187M$ 923M
2023$ 556M-$ 545M$ 568M
2022$ 1.59B-$ 657M$ 1.33B
2021$ 1.14B-$ 1.74B$ 1.51B
2020$ 475M-$ 427M$ 711M
2019$ 18M-$ 130M$ 78M
2018$ 34M-$ 184M$ 70M
2017$ 31M-$ 183M$ 106M
2016$ 15M-$ 279M$ 144M
2015$ 36M-$ 156M$ 230M
2014$ 30M-$ 82M$ 168M
2013$ 20M-$ 51M$ 133M
2012$ 22M-$ 28M$ 44M
2011$ 14M-$ 19M$ 18M
2010$ 343K-$ 35M$ 31M
2009$ 325K-$ 38M$ 42M
2008$ 1M-$ 36M$ 33M
2007$ 1M-$ 34M$ 46M
2006$ 4M-$ 23M$ 73M
2005$ 7M-$ 11M$ 31M
2004$ 8M-$ 25M$ 17M
2003$ 11M-$ 17M$ 27M
2002$ 15M-$ 22M$ 3M
2001$ 24M-$ 9M$ 20M
2000$ 2M-$ 12M$ 14M
1999$ 1M-$ 4M$ 700K
1998$ 700K-$ 4M$ 1M
1997$ 500K-$ 4M$ 3M
1996$ 100K-$ 5M$ 2M
NVAX - Novavax Inc logo

Novavax Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 475M to $ 1.12B and net income went from -$ 427M to $ 440M. Revenue increased in 3 of those 5 years; net income in 4.

Between 2015 and 2025, revenue grew from $ 36M to $ 1.12B and net income went from -$ 156M to $ 440M. Revenue increased in 7 of those 10 years; net income in 6.

Novavax Inc currently holds a 20-year HDB Score of 3.3 out of 10. How the HDB Score is calculated.

Membership

Continue NVAXโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies